Prescription monitoring program provisions modifications

SF 2806 amends Minnesota's prescription monitoring program to expand the list of substances tracked. It adds butalbital, gabapentin, and FDA-approved opioid reversal agents to the "controlled reportable substances" category, requiring pharmacists and prescribers to report data on these drugs. The bill maintains existing electronic reporting requirements for controlled substances, including patient name, date of birth, drug name, strength, quantity, and days supply. This directly affects pharmacies, hospitals, and healthcare providers who dispense these monitored medications, ensuring consistent data collection for program oversight.